File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A morpho-molecular prognostic model for hepatocellular carcinoma

TitleA morpho-molecular prognostic model for hepatocellular carcinoma
Authors
KeywordsLiver Cancer
Microvessel Density
P53
Prognosis
Survival
Issue Date2012
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjc
Citation
British Journal Of Cancer, 2012, v. 107 n. 2, p. 334-339 How to Cite?
AbstractBackground: Hepatocellular carcinoma (HCC) is the third common cause of cancer-related deaths and its prognostication is still suboptimal. The aim of this study was to establish a new prognostication algorithm for HCC. Methods: In all, 13 biomarkers related to the etiopathogenesis of HCC were evaluated by immunohistochemistry using tissue microarrays containing 121 primary HCC resection cases, and validated in subsequent cohort of 85 HCC cases. The results were compared with Affymetrix Gene Chip Human Genome U133Plus microarray data in a separate cohort of 228 HCC patients. Results: On immunohistochemical evaluation and multivariate Cox regression analysis p53, alpha fetaprotein (AFP), CD44 and CD31, tumour size and vascular invasion, were significant predictors for worse survival in HCC patients. A morpho-molecular prognostic model (MMPM) was constructed and it was a significant independent predictor for overall survival (OS) and relapse-free survival (RFS) (P<0.000). The OS and RFS of HCC low was higher (104 and 78 months) as compared with HCC high (73 and 43 months) (P<0.0001for OS and RFS). Hepatocellular carcinoma patients with higher stage (III+IV), >5 cm tumour size, positive vascular invasion and satellitosis belonged to HCC high group. The validation group reproduced the same findings. Gene expression analysis confirmed that 7 of the 12 biomarkers were overexpressed in >50% of tumour samples and significant overexpression in tumour samples was observed in AFP, CD31, CD117 and Ki-67 genes. Conclusion: The MMPM, based on the expression of selected proteins and clinicopathological parameters, can be used to classify HCC patients between good vs poor prognosis and high vs low risk of recurrence following hepatic resection. © 2012 Cancer Research UK All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/173033
ISSN
2023 Impact Factor: 6.4
2023 SCImago Journal Rankings: 3.000
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSrivastava, Sen_US
dc.contributor.authorWong, KFen_US
dc.contributor.authorOng, CWen_US
dc.contributor.authorHuak, CYen_US
dc.contributor.authorYeoh, KGen_US
dc.contributor.authorTeh, Men_US
dc.contributor.authorLuk, JMen_US
dc.contributor.authorSaltoTellez, Men_US
dc.date.accessioned2012-10-30T06:26:44Z-
dc.date.available2012-10-30T06:26:44Z-
dc.date.issued2012en_US
dc.identifier.citationBritish Journal Of Cancer, 2012, v. 107 n. 2, p. 334-339en_US
dc.identifier.issn0007-0920en_US
dc.identifier.urihttp://hdl.handle.net/10722/173033-
dc.description.abstractBackground: Hepatocellular carcinoma (HCC) is the third common cause of cancer-related deaths and its prognostication is still suboptimal. The aim of this study was to establish a new prognostication algorithm for HCC. Methods: In all, 13 biomarkers related to the etiopathogenesis of HCC were evaluated by immunohistochemistry using tissue microarrays containing 121 primary HCC resection cases, and validated in subsequent cohort of 85 HCC cases. The results were compared with Affymetrix Gene Chip Human Genome U133Plus microarray data in a separate cohort of 228 HCC patients. Results: On immunohistochemical evaluation and multivariate Cox regression analysis p53, alpha fetaprotein (AFP), CD44 and CD31, tumour size and vascular invasion, were significant predictors for worse survival in HCC patients. A morpho-molecular prognostic model (MMPM) was constructed and it was a significant independent predictor for overall survival (OS) and relapse-free survival (RFS) (P<0.000). The OS and RFS of HCC low was higher (104 and 78 months) as compared with HCC high (73 and 43 months) (P<0.0001for OS and RFS). Hepatocellular carcinoma patients with higher stage (III+IV), >5 cm tumour size, positive vascular invasion and satellitosis belonged to HCC high group. The validation group reproduced the same findings. Gene expression analysis confirmed that 7 of the 12 biomarkers were overexpressed in >50% of tumour samples and significant overexpression in tumour samples was observed in AFP, CD31, CD117 and Ki-67 genes. Conclusion: The MMPM, based on the expression of selected proteins and clinicopathological parameters, can be used to classify HCC patients between good vs poor prognosis and high vs low risk of recurrence following hepatic resection. © 2012 Cancer Research UK All rights reserved.en_US
dc.languageengen_US
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bjcen_US
dc.relation.ispartofBritish Journal of Canceren_US
dc.subjectLiver Canceren_US
dc.subjectMicrovessel Densityen_US
dc.subjectP53en_US
dc.subjectPrognosisen_US
dc.subjectSurvivalen_US
dc.titleA morpho-molecular prognostic model for hepatocellular carcinomaen_US
dc.typeArticleen_US
dc.identifier.emailLuk, JM: jmluk@hkucc.hku.hken_US
dc.identifier.authorityLuk, JM=rp00349en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1038/bjc.2012.230en_US
dc.identifier.pmid22713659-
dc.identifier.scopuseid_2-s2.0-84863718483en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84863718483&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume107en_US
dc.identifier.issue2en_US
dc.identifier.spage334en_US
dc.identifier.epage339en_US
dc.identifier.isiWOS:000306324600017-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridSrivastava, S=53983491600en_US
dc.identifier.scopusauthoridWong, KF=49362744900en_US
dc.identifier.scopusauthoridOng, CW=24462106600en_US
dc.identifier.scopusauthoridHuak, CY=6506624710en_US
dc.identifier.scopusauthoridYeoh, KG=55171730300en_US
dc.identifier.scopusauthoridTeh, M=7003510243en_US
dc.identifier.scopusauthoridLuk, JM=7006777791en_US
dc.identifier.scopusauthoridSaltoTellez, M=7003434917en_US
dc.identifier.citeulike10824937-
dc.identifier.issnl0007-0920-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats